logo-loader
viewCytoDyn Inc.

CytoDyn anticipates near-term revenue from cell diagnostic company IncellDX

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive Investors the biotech is anticipating revenue as early as August after inking a diagnostic license and supply agreement with cell diagnostic company IncellDX Inc for the use of its PA-14 antibody.

Dr Pourhassan also addressed off-topic questions on timelines for its cancer therapy to treat metastatic triple-negative breast cancer, as well as its recent tender offer.

Quick facts: CytoDyn Inc.

Price: 1.095 USD

OTCMKTS:CYDY
Market: OTCQB
Market Cap: $471.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn forms partnership with Chinese medical services...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biopharma has signed a nonbinding letter of intent with Chinese medical services provider Longen China Group to develop and license its drug leronlimab as a treatment for coronavirus. Pourhassan says its important the...

1 week, 1 day ago

2 min read